pravastatin has been researched along with coenzyme q10 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Carlsen, SM; Fougner, KJ | 1 |
| Agner, E; Leth, A; Mortensen, SA; Rohde, M | 1 |
| Hayakawa, T; Inada, M; Miyake, Y; Nishikawa, M; Omoto, S; Shimizu, H; Shouzu, A; Yonemoto, T | 1 |
| Kaminnaia, VI; Kaminnyĭ, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Tikhaze, AK | 1 |
| Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA | 1 |
| Belenkov, YN; Kaminnyi, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Pisarenko, OI; Shumaev, KB; Tikhaze, AK | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Colquhoun, D; Gay, CA; Nestel, P; Pollicino, C; Simes, J; Stocker, R; Sullivan, D; Tonkin, A; Whiting, M | 1 |
| Ichihara, K | 1 |
| Atanasova, P; Bełtowski, J; Chaldakov, GN; Chylińska-Kula, B; Jamroz-Wiśniewska, A; Wójcicka, G | 1 |
| Itoh, H; Mitsuishi, M; Miyashita, K; Muraki, A; Tamaki, M; Tanaka, K | 1 |
| Ganesan, S; Ito, MK | 1 |
| Asping, M; Dela, F; Dohlmann, TL; Helge, JW; Larsen, S; Stride, N; Søgaard, D | 1 |
1 review(s) available for pravastatin and coenzyme q10
| Article | Year |
|---|---|
[Myocardial dysfunction].
Topics: Animals; Cardiomyopathies; Clinical Trials as Topic; Coenzymes; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Stunning; Myocardium; Oils; Pravastatin; Simvastatin; Solubility; Ubiquinone; Water | 2006 |
5 trial(s) available for pravastatin and coenzyme q10
| Article | Year |
|---|---|
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Topics: Adult; Aged; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coenzymes; Coronary Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Risk Factors; Ubiquinone | 1997 |
Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Chromatography, High Pressure Liquid; Coenzymes; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1999 |
[Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10].
Topics: Antioxidants; Coenzymes; Double-Blind Method; Free Radicals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Ubiquinone | 2000 |
The effect of pravastatin and atorvastatin on coenzyme Q10.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Coenzymes; Coronary Disease; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Triglycerides; Ubiquinone | 2001 |
The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study.
Topics: Adult; Blood Glucose; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Middle Aged; Mitochondria, Muscle; Muscle Fibers, Skeletal; Oxygen Consumption; Pravastatin; Simvastatin; Ubiquinone | 2017 |
8 other study(ies) available for pravastatin and coenzyme q10
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Statin therapy, Q10 and heart failure. Is there any difference between statins?].
Topics: Anticholesteremic Agents; Coenzymes; Heart Failure; Humans; Lovastatin; Pravastatin; Ubiquinone | 1994 |
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Topics: Animals; Antioxidants; Arteriosclerosis; Coenzymes; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins, LDL; Liver; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Probucol; Pyridines; Rats; Time Factors; Ubiquinone; Vitamin E | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study.
Topics: Cardiovascular Diseases; Case-Control Studies; Coenzymes; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Placebos; Pravastatin; Prospective Studies; Recurrence; Regression Analysis; Risk; Ubiquinone | 2006 |
Differential effects of statins on endogenous H2S formation in perivascular adipose tissue.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Cholesterol; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; KATP Channels; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Potassium Channel Blockers; Pravastatin; Pyrroles; Quinone Reductases; Rats; Rats, Wistar; Sulfides; Triglycerides; Ubiquinone; Vasoconstrictor Agents; Vasodilation | 2011 |
Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Cells; Muscle Strength; Muscle, Skeletal; Organ Size; Oxygen Consumption; Physical Conditioning, Animal; Physical Endurance; Pravastatin; Pyrroles; Ubiquinone | 2012 |
Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anticholesteremic Agents; Azetidines; Diabetes Mellitus; Drug Interactions; Ezetimibe; Glucose Transporter Type 4; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Simvastatin; Ubiquinone | 2013 |